Fresh re­port of 'ad­vanced' $40B+ Seagen buy­out talks spurs more buzz about FTC show­down

Mer­ck CEO Rob Davis ap­pears com­mit­ted to push­ing through with a $40 bil­lion (or so) buy­out deal with Seagen, dri­ven by its need to be much more than Keytru­da — and de­spite the like­ly FTC fight to come.

The Wall Street Jour­nal has the lat­est play-by-play call of the pri­vate M&A talks, re­port­ing overnight that Mer­ck is in “ad­vanced” dis­cus­sions to buy Seagen at a share price north of $200. The dead­line ap­pears to be Mer­ck’s Q2 call, set for Ju­ly 28. That was good for an­oth­er 5% spike on Seagen’s share price ahead of the bell, now right around $184 as in­vestors con­sid­er the lat­est buzz.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE